IS1609B - Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina - Google Patents

Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Info

Publication number
IS1609B
IS1609B IS3865A IS3865A IS1609B IS 1609 B IS1609 B IS 1609B IS 3865 A IS3865 A IS 3865A IS 3865 A IS3865 A IS 3865A IS 1609 B IS1609 B IS 1609B
Authority
IS
Iceland
Prior art keywords
intermediates
production
analogous method
benzofuran derivatives
benzofuran
Prior art date
Application number
IS3865A
Other languages
English (en)
Other versions
IS3865A (is
Inventor
Clive Ross Barry
Middlemiss David
Ian Carter Scopes David
Iain Mclean Jack Torquil
Stuart Cardwell Kevin
Dennis Dowle Michael
Bruce Judd Duncan
Paul Watson Stephen
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS3865A publication Critical patent/IS3865A/is
Publication of IS1609B publication Critical patent/IS1609B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS3865A 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina IS1609B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds

Publications (2)

Publication Number Publication Date
IS3865A IS3865A (is) 1992-11-17
IS1609B true IS1609B (is) 1996-10-18

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3865A IS1609B (is) 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Country Status (21)

Country Link
US (2) US5332831A (is)
EP (1) EP0514198B1 (is)
JP (1) JPH06211846A (is)
KR (1) KR920021541A (is)
AP (1) AP318A (is)
AT (1) ATE169297T1 (is)
AU (2) AU654350B2 (is)
BG (1) BG98216A (is)
CA (1) CA2068766A1 (is)
CZ (1) CZ243093A3 (is)
DE (1) DE69226472D1 (is)
FI (1) FI935036A7 (is)
GB (1) GB9110636D0 (is)
IL (1) IL101882A0 (is)
IS (1) IS1609B (is)
MX (1) MX9202281A (is)
NO (1) NO921944L (is)
OA (1) OA09841A (is)
SK (1) SK112893A3 (is)
TW (1) TW221998B (is)
WO (1) WO1992020674A1 (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
NZ511938A (en) 1998-12-23 2004-02-27 Novartis Ag Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
JP2001089393A (ja) * 1999-07-21 2001-04-03 Takeda Chem Ind Ltd 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EP1313470A4 (en) * 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
KR101397289B1 (ko) * 2006-05-05 2014-05-22 다우 글로벌 테크놀로지스 엘엘씨 헤테로시클릭 유기 리간드의 하프늄 착물
CA2662112A1 (en) 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (ja) 2007-04-03 2012-11-14 四国化成工業株式会社 2−ハロイミダゾール化合物の製造方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
CN110256382A (zh) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
AU559687B2 (en) * 1981-07-01 1987-03-19 Upjohn Company, The Pyridinyl-and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd 2,3−ジヒドロベンゾフラン−5−スルホンアミド誘導体および降圧利尿剤
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
KR0163595B1 (ko) * 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
KR950009860B1 (ko) * 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
KR920021542A (ko) * 1991-05-16 1992-12-18 배리 안토니 뉴샘 벤조푸란 유도체
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Also Published As

Publication number Publication date
IS3865A (is) 1992-11-17
TW221998B (is) 1994-04-01
GB9110636D0 (en) 1991-07-03
AP318A (en) 1994-02-15
KR920021541A (ko) 1992-12-18
NO921944L (no) 1992-11-17
WO1992020674A1 (en) 1992-11-26
US5332831A (en) 1994-07-26
MX9202281A (es) 1992-11-01
CA2068766A1 (en) 1992-11-17
US5498722A (en) 1996-03-12
FI935036A0 (fi) 1993-11-15
SK112893A3 (en) 1994-11-09
EP0514198B1 (en) 1998-08-05
NO921944D0 (no) 1992-05-15
IL101882A0 (en) 1992-12-30
AU1632192A (en) 1993-03-11
ATE169297T1 (de) 1998-08-15
DE69226472D1 (de) 1998-09-10
CZ243093A3 (en) 1994-03-16
BG98216A (en) 1994-08-15
AU1692692A (en) 1992-12-30
OA09841A (en) 1994-08-15
FI935036A7 (fi) 1993-11-15
JPH06211846A (ja) 1994-08-02
AU654350B2 (en) 1994-11-03
EP0514198A1 (en) 1992-11-19

Similar Documents

Publication Publication Date Title
IS3865A (is) Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina
IS1713B (is) Hliðstæð aðferð til framleiðslu á andróstenón afleiðu og milliefni til notkunar með aðferðinni
IS4201A (is) Aðferð til framleiðslu á Benzofuran afleiðum
IS1618B (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
IS1867B (is) Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
DK451187D0 (da) Fremgangsmaade og apparat til kraftproduktion
NO177084C (no) Fremgangsmåte og anordning for kontinuerlig fremstilling av absorbente legemer
NO305634B1 (no) FremgangsmÕte og anordning for kake-produksjon
IS3936A (is) Hliðstæð aðferð til framleiðslu á vatnsuppleysanlegum kamptóþesín afleiðum
IS3718A7 (is) Amínóbenzodiazepines og aðferð til framleiðslu þess
IS3823A (is) Ný carboxyl-amid efnasambönd og aðferð til framleiðslu þeirra
NO950412D0 (no) Fremgangsmåte og apparat for fremstilling av tremel, samt anvendelse derav til fremstilling av plater
NO176425C (no) Fremgangsmåte og anordning til kontinuerlig utglödning av amorfe bånd i produksjonslinjen
IS4244A (is) Aðferð til framleiðslu á Indoline afleiðum og notkun þeirra
IS3555A7 (is) Pyrrol-afleiður og aðferð til framleiðslu þeirra
IS3857A (is) Karboxýl-sýruafleiður og aðferð til framleiðslu þeirra
DK0635004T3 (da) 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
IS3969A (is) Hliðstæðar aðferðir til framleiðslu á bensópýran og skyldum LTB4 mótlyfjum
IS3827A (is) Hliðstæð aðferð við framleiðslu á pýrról[2,3 b]pýridínum
IS4980A (is) Aðferðir og milliefni við framleiðslu á setnum krómanól afleiðum
NO174334C (no) Fremgangsmåte og innretning til fremstilling av fiberplater
NO941110D0 (no) Fremgangsmåte og apparat for fremstilling av bioproteiner
IS4033A (is) Hliðstæð aðferð til framleiðslu á isobenzofuranylafleiðum og milliefni til notkunar með aðferðinni